El objetivo de la presente evaluación de tecnología sanitaria (ETS) rápida fue describir la evidencia científica disponible sobre el uso de fingolimod para el tratamiento de la EMRR.

El objetivo de la presente evaluación de tecnología sanitaria (ETS) rápida fue describir la evidencia científica disponible sobre el uso de fingolimod para el tratamiento de la EMRR.

Background: Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema ...

Objectives The aim of this prospective observational postmarketing study was to evaluate fingolimod effectiveness in a real-world setting in Buenos Aires, Argentina. Methods Relapsing remitting multiple sclerosis patients ...

Both proprietary and nonproprietary medicines are expected to undergo rigorous preapproval testing and both should meet stringent health authority regulatory requirements related to quality to obtain approval. Nonproprietary ...

Both proprietary and nonproprietary medicines are expected to undergo rigorous preapproval testing and both should meet stringent health authority regulatory requirements related to quality to obtain approval. Nonproprietary ...